Market Cap : 427.71 M | Enterprise Value : 327.15 M | PE Ratio : 1.63 | PB Ratio : 6.36 |
---|
ICPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ICPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Intercept Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2023 was $-0.770. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-10.63 for the trailing ten years ended in Mar. 2023.
As of today (2023-05-29), Intercept Pharmaceuticals's current stock price is $10.26. Intercept Pharmaceuticals's E10 for the quarter that ended in Mar. 2023 was $-10.63. Intercept Pharmaceuticals's Shiller PE Ratio of today is .
The historical data trend for Intercept Pharmaceuticals's E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Intercept Pharmaceuticals's E10, along with its competitors' market caps and E10 data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's E10 distribution charts can be found below:
* The bar in red indicates where Intercept Pharmaceuticals's E10 falls in comparison to its industry or sector. The grey bar indicates the E10's extreme value range as defined by GuruFocus.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Intercept Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Mar. 2023 (Change) | * | Current CPI (Mar. 2023) |
= | -0.77 | / | 127.3478 | * | 127.3478 | |
= | -0.770 |
Current CPI (Mar. 2023) = 127.3478.
Intercept Pharmaceuticals Quarterly Data
per share eps | CPI | Adj_EPS | |
201306 | -0.790 | 98.518 | -1.021 |
201309 | -1.650 | 98.790 | -2.127 |
201312 | -0.610 | 98.326 | -0.790 |
201403 | -12.610 | 99.695 | -16.108 |
201406 | 1.510 | 100.560 | 1.912 |
201409 | -1.690 | 100.428 | -2.143 |
201412 | -1.630 | 99.070 | -2.095 |
201503 | -1.780 | 99.621 | -2.275 |
201506 | -1.990 | 100.684 | -2.517 |
201509 | -2.100 | 100.392 | -2.664 |
201512 | -3.620 | 99.792 | -4.620 |
201603 | -5.170 | 100.470 | -6.553 |
201606 | -3.140 | 101.688 | -3.932 |
201609 | -3.590 | 101.861 | -4.488 |
201612 | -4.840 | 101.863 | -6.051 |
201703 | -3.610 | 102.862 | -4.469 |
201706 | -3.460 | 103.349 | -4.263 |
201709 | -2.890 | 104.136 | -3.534 |
201712 | -4.430 | 104.011 | -5.424 |
201803 | -3.220 | 105.290 | -3.895 |
201806 | -2.580 | 106.317 | -3.090 |
201809 | -2.180 | 106.507 | -2.607 |
201812 | -2.970 | 105.998 | -3.568 |
201903 | -3.030 | 107.251 | -3.598 |
201906 | -2.280 | 108.070 | -2.687 |
201909 | -2.590 | 108.329 | -3.045 |
201912 | -2.990 | 108.420 | -3.512 |
202003 | -2.860 | 108.902 | -3.344 |
202006 | -1.920 | 108.767 | -2.248 |
202009 | -2.010 | 109.815 | -2.331 |
202012 | -1.580 | 109.897 | -1.831 |
202103 | -1.220 | 111.754 | -1.390 |
202106 | -0.330 | 114.631 | -0.367 |
202109 | -0.110 | 115.734 | -0.121 |
202112 | -1.230 | 117.630 | -1.332 |
202203 | -0.580 | 121.301 | -0.609 |
202206 | -0.250 | 125.017 | -0.255 |
202209 | 7.800 | 125.227 | 7.932 |
202212 | -0.500 | 125.222 | -0.508 |
202303 | -0.770 | 127.348 | -0.770 |
Add all the adjusted EPS together and divide 10 will get our e10.
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Saik | officer: EVP & Chief Financial Officer | 640 LEE ROAD, CHESTERBROOK PA 19087 |
M Michelle Berrey | officer: President, R&D and CMO | 303A COLLEGE ROAD EAST, PRINCETON NJ 08450 |
Dagmar Rosa-bjorkeson | director | C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
Rocco Venezia | officer: Chief Accounting Officer | C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001 |
Lisa Defrancesco | officer: SVP, IR & Corp. Affairs | C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001 |
Linda M Richardson | officer: EVP & Chief Commercial Officer | 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713 |
Jared Freedberg | officer: General Counsel and Secretary | 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Bryan Ball | officer: Chief Quality Officer | 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Paolo Fundaro | director, 10 percent owner | C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123 |
Keith Michael Gottesdiener | director | 900 FIFTH AVENUE, #8C, NEW YORK NY 10021 |
Luca Benatti | director | C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011 |
Daniel G Welch | director | 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707 |
Daniel Bradbury | director | BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037 |
Nancy Miller-rich | director | C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001 |
Gino Santini | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By GuruFocusNews 07-03-2022
By GuruFocusNews 07-01-2022
By Value_Insider 10-25-2022
By Ds*** 08-29-2022
By Tiesvg 12-23-2022
By PurpleRose 07-11-2022
By Value_Insider 11-22-2022
By GuruFocusNews 07-10-2022
Other Sources
By tipranks.com 2023-01-19
By Yahoo Finance 2023-01-04
By Yahoo Finance 2023-01-25
By Zacks 2023-01-13
By Zacks 2023-01-04
By Yahoo Finance 2022-11-01
By Yahoo Finance 2022-11-01
By Zacks 2023-01-20
By Yahoo Finance 2022-12-23
By Yahoo Finance 2023-01-20
By Yahoo Finance 2022-10-30
By Yahoo Finance 2022-10-02
By Yahoo Finance 2022-10-25